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Atrial ﬁbrillation (AF) is the most common human
arrhythmia causing a signiﬁcant public health burden. Res-
toration of sinus rhythm by cardioversion of the arrhythmia,
performed either electrically or pharmacologically, has been
a main therapeutic option for the treatment of AF patients
during the last decades. After publication of several large
randomized studies showing no signiﬁcant beneﬁt of a rhythm
control compared with a rate control strategy in AF patients
(1,2), the number of cardioversions began to decline (3).See page 1187However, recent investigations reported potential advantages
of rhythm control such as a survival beneﬁt after several years
(4) or a reduced progression rate to more permanent AF forms
(5). As a result, the appropriate management of AF patients
remains controversial, with rhythm control being the preferred
strategy in several instances in everyday clinical practice (6,7).
Therefore, issues associated with the safety of cardioversion,
which represents the cornerstone of rhythm control, are of
major clinical importance.
The most feared complications of AF cardioversion are
thromboembolic events, mainly stroke. These events are
caused by 2 mechanisms:
1. The presence of thrombus in the left atrial appendage at
the time of cardioversion as a result of a reduced ﬂow*Editorials published in the Journal of the American College of Cardiology reﬂect the
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and mobilization of this thrombus by cardioversion.
This danger is minimized by administration of anti-
coagulants for several weeks before cardioversion or
alternatively by exclusion of thrombus by trans-
esophageal echocardiography before cardioversion.
2. The so-called “atrial stunning.” This term characterizes
a paradoxical decrease of left atrial and left atrial
appendage function immediately after successful car-
dioversion to sinus rhythm (8). This decline of function
can be visualized as a decrease of the left atrial appendage
emptying velocity measured by transesophageal echo-
cardiography, as new formation of spontaneous echo
contrast, ordinmore severe casesdas formation of new
thrombus in the left atrial appendage.
Atrial stunning is clinically very important, because it is
responsible for the thromboembolic events in the days after
cardioversion. The timing of these events is characteristic, with
the vast majority occurring within 1 week after cardioversion,
and most cases taking place in the ﬁrst 3 days (9). The reason
for the reduction of the thromboembolic risk after this time
interval is the gradual resolution of atrial stunningwith recovery
of the left atrial function as time passes after cardioversion (10).
To prevent thromboembolism as a result of atrial stunning,
anticoagulation after the procedure is of paramount impor-
tance. Therefore, international guidelines recommend effective
anticoagulation for at least 4 weeks after cardioversion (11,12).
Several parameters inﬂuence the time course of the recovery
of left atrial function, with the duration of AF preceding car-
dioversion being a major one among them: a brief duration of
preceding AF (e.g.,<2 weeks) is associated with a more rapid
resolution of atrial stunning (13); and a very brief AF duration
(e.g., 15 min) does not result in any signiﬁcant atrial stunning
(14). But howbrief is safe? In otherwords, up towhichduration
of precedingAFdowe consider the risk of thrombus formation
after cardioversion to be so low that anticoagulation can be
safely omitted? Up to now, there were no robust data providing
an answer to this question. A duration of 48 h was generally
considered a threshold in this regard, and the guidelines
emphasize the necessity of effective anticoagulation both before
and after cardioversion ofAF,with a durationofmore than48h
(11,12). However, there is a knowledge gap for AF, with a
duration of <48 h, and the guidelines recommend in this set-
ting anticoagulation in patients who have risk factors for stroke.
In this issue of the Journal, Airaksinen et al. (15) present the
results of a study that provides a signiﬁcant insight into this
gray ﬁelddnamely, patients undergoing cardioversion with
a duration of preceding AF of <48 h. The investigators
reviewed the data of 5,116 successful cardioversions performed
without peri-procedural and post-cardioversion oral anti-
coagulation or heparin in a total of 2,481 patients with AF
lasting <48 h. Within 30 days after cardioversion, there were
38 deﬁnite embolic events, corresponding to a rate of 0.7%,
and additionally 4 transient ischemic attacks. The time course
of the deﬁnite embolic events was compatible with the time
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1194course observed previously: the events occurred between 1 and
27 days after cardioversion, with amedian of 2 days conﬁrming
that the ﬁrst few days after cardioversion are the ones that carry
the highest risk and that deserve the greatest attention.
Signiﬁcant predictors of embolic events were higher age,
female sex, heart failure, and diabetes. These parameters allowed
a differentiation of the risk, with an unacceptably high risk of
9.8% for patients with heart failure and diabetes, compared with
only 0.2% in young patients (<60 years) without heart failure. It
is important that the parameters, which were identiﬁed as
predictors of subsequent thromboembolic events, are in general
the ones that also predict thromboembolic complications in
the general AF population, and they are included in the
CHA2DS2-VASc (Congestive heart failure, Hypertension,
Age 75 [doubled], Diabetes mellitus, and prior Stroke, tran-
sient ischemic attack, or thromboembolism [doubled], Vascular
disease, Age 65 to 74, Sex category [female] score.
These results have important clinical implications and, to
a signiﬁcant extent, ﬁll the existing knowledge gap. They
prove the correctness of current guidelines, which recom-
mend anticoagulation therapy in patients with risk factors
for stroke even if the AF duration preceding cardioversion is
presumed to be brief and <48 h, because the thromboem-
bolic risk might be unacceptably high in the presence of
certain risk factors. Conversely, it is reassuring that patients
without risk factors for stroke and with a brief duration of
preceding AF had a very low rate of thromboembolic events.
The study has some limitations. The most important one
is the retrospective character of the analysis. However, this
drawback is at least partially compensated by the large
patient number and by the presumably good quality of
the analyzed registries. Furthermore, given the existence of
guidelines recommending anticoagulation in these patients,
namely patients with risk factors for stroke even if the
preceding AF duration is brief, a randomized trial would be
unethical. Thus, retrospective data of good quality are
probably the best we can rely on.
Another inherent limitation,which is not related to the study,
is the high prevalence of asymptomatic AF episodes (16,17).
Thus, the exact duration of a particular AF episode in a given
patient can only be assumed. Nevertheless, the authors provide
interesting data in this regard, showing a low thromboembolic
risk in patients with an assumed AF duration of <48 h and
without risk factors for stroke despite these uncertainties.
In conclusion, the study by Airaksinen et al. convincingly
demonstrates the necessity of effective anticoagulation in
patients with risk factors for stroke even if the duration of
AF preceding cardioversion is assumed to be <48 h.
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